Cancer Research Technology
Log in Register
Menu

Anti-LPP3 [046] monoclonal antibody

Invented at University of Illinois, Chicago

Info

Catalogue Number 156376
Applications FACS IP WB
Antigen/Gene or Protein Targets Lipid Phosphate Phosphohydrolase 3
Synonyms PLPP3, Dri42, PAP2B, VCIP, PPAP2B or phospholipid phosphatase 3
Reactivity Human and Mouse
Relevance An antibody against the extracellular domain of LPP3 inhibits cell-cell interactions and angiogenesis in vitro. In addition, LPP3 not only catalyzes the dephosphorylation of the bioactive lipid sphingosine-1-phosphate (S1P) to generate sphingosine but also may regulate embryonic development and angiogenesis via the Wnt pathway. LPP3 also has the ability to potentiate tumor growth by amplifying B-catenin and CYCLIN-D1 activities. Thus, LPP3 is a potential target for inhibiting the growth of glioblastoma, an aggressive type of brain tumor, and other LPP3-expressing tumors. This may serve as a link in the acquisition of proliferative, invasive, and metastatic phenotypes.
Host Mouse
Immunogen A modified synthetic peptide (YRCRGDDSKVQEARKSFFc-KLH) corresponding to 179-196 of human LPP3 conjugated to keyhole limpet hemocyanin
Positive Control IgG1
Research Area Adhesion, Cancer, Cell Signaling & Signal Transduction, Cell Structure and Motility

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Humtsoe et al. 2010. Mol Cell Biol. 30(7):1593-606. PMID: 20123964.


Add a reference

References: 1 entry

Humtsoe et al. 2010. Mol Cell Biol. 30(7):1593-606. PMID: 20123964.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor